- Home
- LASR vs ERAS Comparison
LASR vs ERAS Comparison
Compare LASR & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LASR
- ERAS
- Stock Information
- Founded
- LASR 2000
- ERAS 2018
- Country
- LASR United States
- ERAS United States
- Employees
- LASR N/A
- ERAS N/A
- Industry
- LASR Semiconductors
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- LASR Technology
- ERAS Health Care
- Exchange
- LASR Nasdaq
- ERAS Nasdaq
- Market Cap
- LASR 412.8M
- ERAS 348.4M
- IPO Year
- LASR 2018
- ERAS 2021
- Fundamental
- Price
- LASR $18.88
- ERAS $1.54
- Analyst Decision
- LASR Strong Buy
- ERAS Strong Buy
- Analyst Count
- LASR 5
- ERAS 6
- Target Price
- LASR $17.70
- ERAS $4.83
- AVG Volume (30 Days)
- LASR 873.6K
- ERAS 1.2M
- Earning Date
- LASR 07-31-2025
- ERAS 08-11-2025
- Dividend Yield
- LASR N/A
- ERAS N/A
- EPS Growth
- LASR N/A
- ERAS N/A
- EPS
- LASR N/A
- ERAS N/A
- Revenue
- LASR $205,689,000.00
- ERAS N/A
- Revenue This Year
- LASR $13.20
- ERAS N/A
- Revenue Next Year
- LASR $8.66
- ERAS N/A
- P/E Ratio
- LASR N/A
- ERAS N/A
- Revenue Growth
- LASR 2.66
- ERAS N/A
- 52 Week Low
- LASR $6.20
- ERAS $1.01
- 52 Week High
- LASR $20.17
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- LASR 63.30
- ERAS 58.61
- Support Level
- LASR $18.64
- ERAS $1.38
- Resistance Level
- LASR $20.17
- ERAS $1.49
- Average True Range (ATR)
- LASR 0.86
- ERAS 0.11
- MACD
- LASR -0.22
- ERAS 0.01
- Stochastic Oscillator
- LASR 69.94
- ERAS 96.97
About LASR nLIGHT Inc.
nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products, which includes semiconductor lasers, fiber lasers, and directed energy products; and Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.